Zoetis Inc. (ZTS)
USD 167.01
(-2.21%)
USD 167.01
(-2.21%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.83 Billion USD | 3.7% |
| 2022 | 5.62 Billion USD | 2.8% |
| 2021 | 5.47 Billion USD | 18.51% |
| 2020 | 4.61 Billion USD | 8.2% |
| 2019 | 4.26 Billion USD | 9.04% |
| 2018 | 3.91 Billion USD | 10.82% |
| 2017 | 3.53 Billion USD | 9.62% |
| 2016 | 3.22 Billion USD | 6.44% |
| 2015 | 3.02 Billion USD | -1.34% |
| 2014 | 3.06 Billion USD | 6.09% |
| 2013 | 2.89 Billion USD | 4.29% |
| 2012 | 2.77 Billion USD | 7.44% |
| 2011 | 2.58 Billion USD | 20.72% |
| 2010 | 2.13 Billion USD | 27.11% |
| 2009 | 1.68 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.51 Billion USD | 4.28% |
| 2024 Q3 | 1.68 Billion USD | 1.75% |
| 2024 Q2 | 1.65 Billion USD | 9.8% |
| 2023 Q1 | 1.41 Billion USD | 1.8% |
| 2023 Q3 | 1.51 Billion USD | -3.81% |
| 2023 Q4 | 1.44 Billion USD | -4.3% |
| 2023 FY | 5.83 Billion USD | 3.7% |
| 2023 Q2 | 1.57 Billion USD | 11.4% |
| 2022 Q3 | 1.39 Billion USD | -2.24% |
| 2022 Q4 | 1.38 Billion USD | -0.57% |
| 2022 Q1 | 1.41 Billion USD | 3.66% |
| 2022 FY | 5.62 Billion USD | 2.8% |
| 2022 Q2 | 1.42 Billion USD | 0.71% |
| 2021 Q3 | 1.4 Billion USD | 1.74% |
| 2021 Q2 | 1.38 Billion USD | 4.39% |
| 2021 Q1 | 1.32 Billion USD | 9.62% |
| 2021 FY | 5.47 Billion USD | 18.51% |
| 2021 Q4 | 1.36 Billion USD | -2.64% |
| 2020 Q3 | 1.24 Billion USD | 13.04% |
| 2020 FY | 4.61 Billion USD | 8.2% |
| 2020 Q4 | 1.2 Billion USD | -2.74% |
| 2020 Q1 | 1.07 Billion USD | -6.03% |
| 2020 Q2 | 1.09 Billion USD | 2.05% |
| 2019 Q4 | 1.14 Billion USD | 3.53% |
| 2019 Q3 | 1.1 Billion USD | 2.13% |
| 2019 FY | 4.26 Billion USD | 9.04% |
| 2019 Q1 | 937 Million USD | -8.14% |
| 2019 Q2 | 1.08 Billion USD | 15.47% |
| 2018 Q3 | 1 Billion USD | 4.03% |
| 2018 Q2 | 968 Million USD | 5.33% |
| 2018 Q1 | 919 Million USD | -8.37% |
| 2018 FY | 3.91 Billion USD | 10.82% |
| 2018 Q4 | 1.02 Billion USD | 1.29% |
| 2017 Q4 | 1 Billion USD | 9.98% |
| 2017 Q1 | 788 Million USD | -2.6% |
| 2017 FY | 3.53 Billion USD | 9.62% |
| 2017 Q2 | 829 Million USD | 5.2% |
| 2017 Q3 | 912 Million USD | 10.01% |
| 2016 Q4 | 809 Million USD | -2.65% |
| 2016 FY | 3.22 Billion USD | 6.44% |
| 2016 Q3 | 831 Million USD | 2.72% |
| 2016 Q2 | 809 Million USD | 4.66% |
| 2016 Q1 | 773 Million USD | -0.64% |
| 2015 FY | 3.02 Billion USD | -1.34% |
| 2015 Q4 | 778 Million USD | -1.89% |
| 2015 Q3 | 793 Million USD | 6.02% |
| 2015 Q2 | 748 Million USD | 5.65% |
| 2015 Q1 | 708 Million USD | -14.6% |
| 2014 Q2 | 745 Million USD | 3.76% |
| 2014 Q1 | 718 Million USD | -8.88% |
| 2014 FY | 3.06 Billion USD | 6.09% |
| 2014 Q4 | 829 Million USD | 6.83% |
| 2014 Q3 | 776 Million USD | 4.16% |
| 2013 Q1 | 688 Million USD | -7.4% |
| 2013 Q2 | 698 Million USD | 1.45% |
| 2013 FY | 2.89 Billion USD | 4.29% |
| 2013 Q3 | 718 Million USD | 2.87% |
| 2013 Q4 | 788 Million USD | 9.75% |
| 2012 Q2 | 716 Million USD | 9.48% |
| 2012 Q3 | 660 Million USD | -7.82% |
| 2012 Q4 | 743 Million USD | 12.58% |
| 2012 FY | 2.77 Billion USD | 7.44% |
| 2012 Q1 | 654 Million USD | -7.63% |
| 2011 Q4 | 708 Million USD | 8.76% |
| 2011 Q2 | 620 Million USD | 2.99% |
| 2011 FY | 2.58 Billion USD | 20.72% |
| 2011 Q1 | 602 Million USD | 0.0% |
| 2011 Q3 | 651 Million USD | 5.0% |
| 2010 FY | 2.13 Billion USD | 27.11% |
| 2009 FY | 1.68 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 820.56 Million USD | -610.974% |
| Bausch Health Companies Inc. | 6.19 Billion USD | 5.873% |
| Catalent, Inc. | 953 Million USD | -512.172% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -1596.423% |
| Elanco Animal Health Incorporated | 2.48 Billion USD | -134.674% |
| Perrigo Company plc | 1.68 Billion USD | -247.179% |
| Teva Pharmaceutical Industries Limited | 7.64 Billion USD | 23.699% |